纤维蛋白原在创伤性大失血救治中的研究进展*

doi:10.3969/j.issn.1671-2587.2024.02.018

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (2): 274-281.DOI: 10.3969/j.issn.1671-2587.2024.02.018

纤维蛋白原在创伤性大失血救治中的研究进展^*

尚玮, 汪德清

解放军总医院第一医学中心输血医学科,北京 100853

收稿日期:2024-01-25 出版日期:2024-04-20 发布日期:2024-04-23
通讯作者: 汪德清,主任医师,教授,博士生导师,主要从事临床输血风险控制研究,（E-mail）deqingw@vip.sina.com。
作者简介:尚玮,主要从事临床输血风险控制研究,（E-mail）sunvary@163.com。
基金资助:
*本课题受“十三五”军事重大专项的子项目（No.BWS16J006）资助

The Development Fibrinogen in the Treatment of Massive Traumatic Hemorrhage

SHANG Wei, WANG Deqing

Department of Transfusion Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing 100853

Received:2024-01-25 Online:2024-04-20 Published:2024-04-23

摘要/Abstract

摘要： 纤维蛋白原是机体血液循环中浓度最高的凝血蛋白质,在创伤性大失血的救治过程中,纤维蛋白原不仅作为主要止血成分发挥着迅速止血的作用,越来越多的证据显示其对机体的炎症免疫的靶细胞及抗微生物感染过程均发挥着重要的调节作用,本文拟从纤维蛋白原对急性创伤性大失血早、晚期生存率影响的角度对其多重作用进行综述,旨在为早期足量开展纤维蛋白原替代治疗提供更多理论支持。

关键词: 纤维蛋白原, 血小板, 创伤性大失血, 创伤性内皮病, 脓毒症

Abstract: Fibrinogen is a coagulation protein with the highest concentration in the blood circulation. During the treatment of massive traumatic hemorrhage, more and more evidence showed that fibrinogen played a key role not only as the main hemostatic component, but also as a regulator in inflammatory immunity and the anti-microbial infection. This article provides a brief overview of the multiple function of fibrinogen in the treatment of massive traumatic hemorrhage from the prospective of its influence on the early and late mortality, aiming to provide more theoretical supports to the early and sufficient fibrinogen replacement.

Key words: Fibrinogen, Platelet, Massive traumatic hemorrhage, Endotheliopathy of trauma, Sepsis

中图分类号:

R457

尚玮, 汪德清. 纤维蛋白原在创伤性大失血救治中的研究进展^*[J]. 临床输血与检验, 2024, 26(2): 274-281.

SHANG Wei, WANG Deqing. The Development Fibrinogen in the Treatment of Massive Traumatic Hemorrhage[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 274-281.

参考文献

[1] World Health Organization.Global Health Estimates: Life expectancy and leading causes of death and disability[EB/OL].[2024-04-07].http://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates.
[2] SCHUBERT F D,GABBE L J,BJURLIN M A,et al.Differences in trauma mortality between ACS-verified and state-designated trauma centers in the US[J].Injury,2019,50(1):186-191.
[3] TRUNKEY D D.Trauma.Accidental and intentional injuries account for more years of life lost in the U.S.than cancer and heart disease.Among the prescribed remedies are improved preventive efforts,speedier surgery and further research[J].Sci Am,1983,249(2):28-35.
[4] DI SAVERIO S,GAMBALE G,COCCOLINI F,et al.Changes in the outcomes of severe trauma patients from 15-year experience in a Western European trauma ICU of Emilia Romagna Region (1996-2010).A population cross-sectional survey study[J].Langenbeck's Arch Surg,2014,399(1):109-126.
[5] LEE J H,WARD K R.Blood failure: traumatic hemo-rrhage and the interconnections between oxygen debt, endotheliopathy, and coagulopathy[J]. Clin Exp Emerg Med,2024,11(1):9-21.
[6] MENGOLI C,FRANCHINI M,MARANO G,et al.The use of fibrinogen concentrate for the management of trauma-related bleeding:a systematic review and meta-analysis[J].Blood Transfus,2017,15(4):318-324.
[7] HAGEMO J S,STANWORTH S,JUFFERMANS N P,et al.Prevalence,predictors and outcome of hypofibrinogenaemia in trauma:a multicentre observational study[J].Crit Care,2014,18(2):R52.
[8] MOORE E E,MOORE H B,KORNBLITH L Z,et al.Trauma-induced coagulopathy[J].Nat Rev Dis Primers,2021,7(1):30.
[9] CURRY N.Fibrinogen replacement in haemostatic resuscitation:dose,laboratory targets and product choice[J].Transfus Med Rev,2021,35(4):104-107.
[10] SCHLIMP C J,VOELCKEL W,INABA K,et al.Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/- fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma:a retrospective study[J].Scand J Trauma Resusc Emerg Med,2013,21:74.
[11] ASEHNOUNE K,BALOGH Z,CITERIO G,et al.The research agenda for trauma critical care[J].Intensive Care Med,2017,43(9):1340-1351.
[12] HOLCOMB J B,DEL JUNCO D J,FOX E E,et al.The prospective,observational,multicenter,major trauma transfusion (PROMMTT) study:comparative effectiveness of a time-varying treatment with competing risks[J].JAMA Surg,2013,148(2):127-136.
[13] WU F,KOZAR R A.Fibrinogen protects against barrier dysfunction through maintaining cell surface syndecan-1 in vitro[J].Shock,2019,51(6):740-744.
[14] YU Q,YANG B B,DAVIS J M,et al.Identification of fibrinogen as a key anti-apoptotic factor in human fresh frozen plasma for protecting endothelial cells in vitro[J].Shock,2020,53(5):646-652.
[15] BARRY M,TRIVEDI A,MIYAZAWA B Y,et al.Cryoprecipitate attenuates the endotheliopathy of trauma in mice subjected to hemorrhagic shock and trauma[J].J Trauma Acute Care Surg,2021,90(6):1022-1031.
[16] WU F,CHIPMAN A,PATI S,et al.Resuscitative strategies to modulate the endotheliopathy of trauma:from cell to patient[J].Shock,2020,53(5):575-584.
[17] DOUIN D J,FERNANDEZ-BUSTAMANTE A.Early fibrinogen replacement to treat the endotheliopathy of trauma:novel resuscitation strategies in severe trauma[J].Anesthesiology,2023,139(5):675-683.
[18] DOBSON G P,MORRIS J L,LETSON H L.Immune dysfunction following severe trauma:a systems failure from the central nervous system to mitochondria[J].Front Med (Lausanne),2022,9:968453.
[19] BLOCK H,ROSSAINT J,ZARBOCK A.The fatal circle of NETs and NET-associated DAMPs contributing to organ dysfunction[J].Cells,2022,11(12):1919.
[20] CANNON J W,KHAN M A,RAJA A S,et al.Damage control resuscitation in patients with severe traumatic hemorrhage:a practice management guideline from the Eastern Association for the Surgery of Trauma[J].J Trauma Acute Care Surg,2017,82(3):605-617.
[21] LOCKE M,FRANCIS R J,TSAOUSI E,et al.Fibrinogen protects neutrophils from the cytotoxic effects of histones and delays neutrophil extracellular trap formation induced by ionomycin[J].Sci Rep,2020,10(1):11694.
[22] LOWE G D O,RUMLEY A,MACKIE I J.Plasma fibrinogen[J].Ann Clin Biochem,2004,41(Pt 6):430-440.
[23] TENNENT G A,BRENNAN S O,STANGOU A J,et al.Human plasma fibrinogen is synthesized in the liver[J].Blood,2007,109(5):1971-1974.
[24] WEISEL J W,LITVINOV R I.Fibrin formation,structure and properties[J].Subcell Biochem,2017,82:405-456.
[25] LITVINOV R I,FARRELL D H,WEISEL J W,et al.The platelet integrin αIIbβ3 differentially interacts with fibrin versus fibrinogen[J].J Biol Chem,2016,291(15):7858-7867.
[26] BUITRAGO L,ZAFAR H,ZHANG Y X,et al.Dominant role of αIIbβ3 in platelet interactions with cross-linked fibrin fragment D-dimer[J].Blood Adv,2020,4(13):2939-2949.
[27] SUADES R,PADRÓ T,VILAHUR G,et al.Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques[J].Thromb Haemost,2012,108(6):1208-1219.
[28] LEVY J H,WELSBY I,GOODNOUGH L T.Fibrinogen as a therapeutic target for bleeding:a review of critical levels and replacement therapy[J].Transfusion,2014,54(5):1389-1405;quiz 1388.
[29] SCHLIMP C J,VOELCKEL W,INABA K,et al.Estimation of plasma fibrinogen levels based on hemoglobin,base excess and Injury Severity Score upon emergency room admission[J].Crit Care,2013,17(4):R137.
[30] WHITE N J,CONTAIFER D Jr,MARTIN E J,et al.Early hemostatic responses to trauma identified with hierarchical clustering analysis[J].J Thromb Haemost,2015,13(6):978-988.
[31] ZIEGLER B,BACHLER M,HABERFELLNER H,et al.Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC):a multicentre,double-blind,placebo-controlled,randomised pilot study[J].Eur J Anaesthesiol,2021,38(4):348-357.
[32] MCQUILTEN Z K,WOOD E M,BAILEY M,et al.Fibrinogen is an independent predictor of mortality in major trauma patients:a five-year statewide cohort study[J].Injury,2017,48(5):1074-1081.
[33] INABA K,KARAMANOS E,LUSTENBERGER T,et al.Impact of fibrinogen levels on outcomes after acute injury in patients requiring a massive transfusion[J].J Am Coll Surg,2013,216(2):290-297.
[34] KARLSSON M,TERNSTRÖM L,HYLLNER M,et al.Plasma fibrinogen level,bleeding,and transfusion after on-pump coronary artery bypass grafting surgery:a prospective observational study[J].Transfusion,2008,48(10):2152-2158.
[35] STINGER H K,SPINELLA P C,PERKINS J G,et al.The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital[J].J Trauma,2008,64(2 Suppl):S79-S85;discussion S85.
[36] SCHÖCHL H,NIENABER U,MAEGELE M,et al.Transfusion in trauma:thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy[J].Crit Care,2011,15(2):R83.
[37] SCHÖCHL H,NIENABER U,HOFER G,et al.Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate[J].Crit Care,2010,14(2):R55.
[38] ROURKE C,CURRY N,KHAN S,et al.Fibrinogen levels during trauma hemorrhage,response to replacement therapy,and association with patient outcomes[J].J Thromb Haemost,2012,10(7):1342-1351.
[39] INNERHOFER P,FRIES D,MITTERMAYR M,et al.Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC):a single-centre,parallel-group,open-label,randomised trial[J].Lancet Haematol,2017,4(6):e258-e271.
[40] CHANG R,KERBY J D,KALKWARF K J,et al.Earlier time to hemostasis is associated with decreased mortality and rate of complications:results from the Pragmatic Randomized Optimal Platelet and Plasma Ratio trial[J].J Trauma Acute Care Surg,2019,87(2):342-349.
[41] PERALTA R,VIJAY A,EL-MENYAR A,et al.Early high ratio platelet transfusion in trauma resuscitation and its outcomes[J].Int J Crit Illn Inj Sci,2016,6(4):188-193.
[42] TAUBER H,INNERHOFER N,VON LANGEN D,et al.Dynamics of platelet counts in major trauma:the impact of haemostatic resuscitation and effects of platelet transfusion-a sub-study of the randomized controlled RETIC trial[J].J Clin Med,2020,9(8):2420.
[43] ROSSAINT R,AFSHARI A,BOUILLON B,et al.The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition[J].Crit Care,2023,27(1):80.
[44] ROLFES V,RIBEIRO L S,HAWWARI I,et al.Platelets fuel the inflammasome activation of innate immune cells[J].Cell Rep,2020,31(6):107615.
[45] CARESTIA A,MENA H A,OLEXEN C M,et al.Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice[J].Cell Rep,2019,28(4):896-908.e5.
[46] GONZALEZ RODRIGUEZ E,OSTROWSKI S R,CARDENAS J C,et al.Syndecan-1:a quantitative marker for the endotheliopathy of trauma[J].J Am Coll Surg,2017,225(3):419-427.
[47] JOHANSSON P I,STENSBALLE J,RASMUSSEN L S,et al.A high admission syndecan-1 level,a marker of endothelial glycocalyx degradation,is associated with inflammation,protein C depletion,fibrinolysis,and increased mortality in trauma patients[J].Ann Surg,2011,254(2):194-200.
[48] NAUMANN D N,HAZELDINE J,DAVIES D J,et al.Endotheliopathy of trauma is an on-scene phenomenon,and is associated with multiple organ dysfunction syndrome:a prospective observational study[J].Shock,2018,49(4):420-428.
[49] HIPPENSTEEL J A,UCHIMIDO R,TYLER P D,et al.Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation[J].Crit Care,2019,23(1):259.
[50] HATTON G E,DU R E,PEDROZA C,et al.Choice of reference creatinine for post-traumatic acute kidney injury diagnosis[J].J Am Coll Surg,2019,229(6):580-588.e4.
[51] HATTON G E,ISBELL K D,HENRIKSEN H H,et al.Endothelial dysfunction is associated with increased incidence,worsened severity,and prolonged duration of acute kidney injury after severe trauma[J].Shock,2021,55(3):311-315.
[52] PATI S,MATIJEVIC N,DOURSOUT M F,et al.Protective effects of fresh frozen plasma on vascular endothelial permeability,coagulation,and resuscitation after hemorrhagic shock are time dependent and diminish between days 0 and 5 after thaw[J].J Trauma,2010,69(Suppl 1):S55-S63.
[53] HAYWOOD-WATSON R J,HOLCOMB J B,GONZALEZ E A,et al.Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation[J].PLoS One,2011,6(8):e23530.
[54] PENG Z L,PATI S,POTTER D,et al.Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1[J].Shock,2013,40(3):195-202.
[55] WU F,PENG Z L,PARK P W,et al.Loss of syndecan-1 abrogates the pulmonary protective phenotype induced by plasma after hemorrhagic shock[J].Shock,2017,48(3):340-345.
[56] CHIPMAN A M,WU F,KOZAR R A.Fibrinogen inhibits microRNA-19b,a novel mechanism for repair of haemorrhagic shock-induced endothelial cell dysfunction[J].Blood Transfus,2021,19(5):420-427.
[57] WU F,CHIPMAN A,DONG J F,et al.Fibrinogen activates PAK1/cofilin signaling pathway to protect endothelial barrier integrity[J].Shock,2021,55(5):660-665.
[58] WU F,DORMAN B,ZEINEDDIN A,et al.Fibrinogen inhibits metalloproteinase-9 activation and syndecan-1 cleavage to protect lung function in ApoE null mice after hemorrhagic shock[J].J Surg Res,2023,288:208-214.
[59] ZEINEDDIN A,WU F,DONG J F,et al.Early lyophilized cryoprecipitate enhances the ADAMTS13/VWF ratio to reduce systemic endotheliopathy and lessen lung injury in a mouse multiple-trauma hemorrhage model[J].J Trauma Acute Care Surg,2023,95(2S Suppl 1):S137-S143.
[60] CAPPENBERG A,KARDELL M,ZARBOCK A.Selectin-mediated signaling-shedding light on the regulation of integrin activity in neutrophils[J].Cells,2022,11(8):1310.
[61] DENNING N L,AZIZ M,GURIEN S D,et al.DAMPs and NETs in sepsis[J].Front Immunol,2019,10:2536.
[62] ZHENG Y,ZHU Y F,LIU X,et al.The screening of albumin as a key serum component in preventing release of neutrophil extracellular traps by selectively inhibiting mitochondrial ROS generation[J].Can J Physiol Pharmacol,2021,99(4):427-438.
[63] MACRAE F L,DUVAL C,PAPAREDDY P,et al.A fibrin biofilm covers blood clots and protects from microbial invasion[J].J Clin Invest,2018,128(8):3356-3368.
[64] NEGRÓN O,FLICK M J.Does fibrinogen serve the host or the microbe in Staphylococcus infection[J].Curr Opin Hematol,2019,26(5):343-348.
[65] SUN H M,WANG X X,DEGEN J L,et al.Reduced thrombin generation increases host susceptibility to group A streptococcal infection[J].Blood,2009,113(6):1358-1364.
[66] MULLARKY I K,SZABA F M,BERGGREN K N,et al.Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis[J].Infect Immun,2005,73(7):3888-3895.
[67] PRASAD J M,GORKUN O V,RAGHU H,et al.Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense[J].Blood,2015,126(17):2047-2058.
[68] SUN H M,RINGDAHL U,HOMEISTER J W,et al.Plasminogen is a critical host pathogenicity factor for group A streptococcal infection[J].Science,2004,305(5688):1283-1286.

纤维蛋白原在创伤性大失血救治中的研究进展^*

The Development Fibrinogen in the Treatment of Massive Traumatic Hemorrhage

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	中国输血协会临床输血管理学专业委员会. 术前深度单采自体红细胞和/或血小板储血技术应用中国专家共识[J]. 临床输血与检验, 2024, 26(2): 145-155.
[2]	张雷英, 于洋. ABO不同型血浆输注的风险认知与临床实践进展[J]. 临床输血与检验, 2024, 26(2): 164-172.
[3]	陈鑫, 邵小宝, 薛昌雯, 周琳, 朱培元. 丹参酮ⅡA抑制血小板与肿瘤细胞相互作用的实验研究^*[J]. 临床输血与检验, 2024, 26(2): 187-195.
[4]	谢慧晗, 邵小宝, 陈鑫, 周琳, 朱培元. 红景天苷用于单采血小板保存的研究^*[J]. 临床输血与检验, 2024, 26(2): 196-204.
[5]	薛昌雯, 邵小宝, 陈鑫, 周琳, 朱培元. 银杏内酯B抑制血小板与肿瘤细胞相互作用的实验研究^*[J]. 临床输血与检验, 2024, 26(2): 205-212.
[6]	严美玲, 朱培元. 基于网络药理学与分子对接探讨桃红四物汤对血小板活化的作用机制^*[J]. 临床输血与检验, 2024, 26(2): 213-222.
[7]	中国生物医学工程学会血液疗法与工程分会, 中国整形美容协会毛发医学分会, 富血小板血浆创新技术脱发治疗项目组. 自体单采富血小板血浆在脱发治疗中的临床应用专家共识^*[J]. 临床输血与检验, 2024, 26(1): 1-7.
[8]	阳雪新, 魏亚明. ABO非同型血小板输注的现状及建议^*[J]. 临床输血与检验, 2024, 26(1): 17-22.
[9]	阳雪新, 袁咏梅, 吴兆勇, 苑召虎, 刘珍, 童欣欣, 陈小卫, 魏亚明. ABO次侧不相合血小板输注的有效性和安全性初步研究^*[J]. 临床输血与检验, 2024, 26(1): 42-48.
[10]	陈旭升, 杨永涛. 富血小板血浆凝胶在5例糖尿病患者难愈性植入物外露创面的临床应用[J]. 临床输血与检验, 2024, 26(1): 123-126.
[11]	张乃红, 蔡培飞, 刘夏, 李健, 费忠化. 自体血小板分离回输与异体血小板输注在急性A型主动脉夹层手术中的有效性比较^*[J]. 临床输血与检验, 2023, 25(6): 738-742.
[12]	李丽, 刘晓庆, 孙玉艾, 李松芯. 不同补钙方式对固定献血者血清Ca²⁺及PTH的影响分析[J]. 临床输血与检验, 2023, 25(6): 798-801.
[13]	王笑欢, 郭凯, 刘倩, 牛子健, 王孟键, 郭婧, 马曙轩. 凝血和血小板功能分析仪在检测川崎病患儿不同时期凝血功能中的应用[J]. 临床输血与检验, 2023, 25(5): 607-612.
[14]	刘铮, 孙亚敏, 邵树军, 康轶青, 王子清, 李建斌. 血小板输注无效患者的HLA-I类抗体特性分析^*[J]. 临床输血与检验, 2023, 25(5): 631-635.
[15]	华敏玉, 丁月平, 王振兴, 李丽, 赵冬梅, 刘伟, 严婷婷, 温珊, 沈有华, 朱丽莉, 赵兰青, 杨崇, 胡秀兰, 胡官林, 任素玲, 史亚平, 潘阳春, 徐爱华, 高宏, 张涵雪, 夏晶晶, 王文志, 范丽莉, 马学超, 邱艳. 新冠疫情对我国地市级血站单采血小板采集供应的影响[J]. 临床输血与检验, 2023, 25(5): 641-647.